Lannett Company Inc (LCI.N) Quote| Reuters.com
Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

24.23USD
24 Jun 2016
Change (% chg)

$-0.92 (-3.66%)
Prev Close
$25.15
Open
$23.78
Day's High
$24.77
Day's Low
$23.75
Volume
358,015
Avg. Vol
220,918
52-wk High
$62.87
52-wk Low
$16.93

LCI.N

Chart for LCI.N

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company's products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with... (more)

Overall

Beta: 1.79
Market Cap(Mil.): $890.39
Shares Outstanding(Mil.): 36.75
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): 12.07 32.69 34.11
EPS (TTM): 2.01 -- --
ROI: 7.51 15.00 14.23
ROE: 15.43 16.08 15.46

BRIEF-Lannett Co enters into amendment No. 1 to credit, guaranty agreement

* On June 17, Lannett entered into amendment No. 1 to credit and guaranty agreement - sec filing

Jun 20 2016

BRIEF-Lannett to amend credit agreement to repurchase remaining $200 mln of 12 pct senior notes

* Lannett to amend credit agreement to repurchase remaining $200 million of 12% senior notes

Jun 14 2016

BRIEF-Lannett receives FDA approval for neomycin sulfate tablets USP, 500 mg

* Lannett receives FDA approval for neomycin sulfate tablets USP, 500 mg

Jun 13 2016

BRIEF-Lannett says to voluntarily pay down $50 mln of 12% senior notes

* Lannett to voluntarily pay down $50 million of 12% senior notes

May 26 2016

BRIEF-Lannett Company Q3 adj earnings per share $0.75

* Q3 earnings per share view $0.63 -- Thomson Reuters I/B/E/S

May 03 2016

BRIEF-Lannett to co-develop generic insulin product for U.S. market

* Develop a generic insulin pharmaceutical product for u.s. Market with yichang hec changjiang pharmaceutical

Apr 22 2016

BRIEF-Lannett Announces Departure of President Michael Bogda

* President, Michael J. Bogda , is leaving company, effective June 3, 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 11 2016

BRIEF-Lannett receives FDA approvals for two products

* Expects to launch temolozomide capsules shortly Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Mar 29 2016

BRIEF-Lannett sees 2016 net sales in range of $555 mln to $565 mln

* Now expect operating performance for fiscal 2016 full year will be below previous expectations

Mar 23 2016

BRIEF-Lannett reviews sales projections for fiscal 2016

* Says actions to generate synergies, streamline operations, improve efficiencies and significantly reduce costs are on track

Mar 14 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.